FDA 483 - UPMC Susquehanna - March 29, 2018
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of UPMC Susquehanna's Institutional Review Board (IRB) revealed several significant deficiencies. The firm failed to ensure proper IRB composition with unaffiliated members, did not consistently conduct timely continuing reviews of research protocols, and lacked a method for advising IRB members of expedited approvals. Additionally, the inspection found issues with maintaining written IRB procedures and including required FDA inspection statements in informed consent documents.
ID · 1e81d36c-2a6e-4a6e-b694-299441db9521